José Molina
@josemolinagb.bsky.social
1.6K followers 780 following 150 posts
ID doc & Antibiotic Steward • • Clinical trials and #FOAMed believer • Now on @shorten2trial.bsky.social #AMSsky #IDSky #AMR Hospital Virgen del Rocío • Seville, Spain 🇪🇸
Posts Media Videos Starter Packs
Pinned
josemolinagb.bsky.social
Do AMS really work in transplant units and what is yet to be done?

Happy to share our systematic review in @eclinicalmed.bsky.social which we hope will support AB stewardship implementation in SOT units and future research steps #AMSsky #TxID #IDsky

kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...
Reposted by José Molina
seanong.bsky.social
Our new paper in @cmijournal.bsky.social led by the brilliant Hadrien Moffroid, a junior colleague in Melbourne. We examined international funding flows in ID RCTs published in selected high-impact journals over a 10-year period.

doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
Heat map of countries funding ID clinical trials and countries where ID clinical trials are conducted.
Reposted by José Molina
escmid.bsky.social
We are now accepting applications for the role of Guidelines Director. This honorary position is responsible for overseeing the entire ESCMID Guidelines portfolio with the support of the Guidelines Counsellor and Subcommittee. Learn more and apply today! ow.ly/Oz2a50WTNSC

#IDSky #clinmicro
Reposted by José Molina
madhupai.bsky.social
We all need some good news

👏🏽👏🏽👏🏽

“The revolutionary HIV prevention tool, injectable lenacapavir, will be available at a cost of US$40 a year in 120 low- and middle-income countries starting in 2027”

@unitaid.bsky.social CHAI Wits RHI

unitaid.org/news-blog/le...
Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs - Unitaid
unitaid.org
Reposted by José Molina
jac-amr.bsky.social
Prolonged IV antibiotics aren’t just a patient safety issue - they generate considerable CO₂e
#AMS is climate action
doi.org/10.1093/jaca...
#JACAMRNews #Stewardship #Sustainability #IDSky @saiedali.bsky.social
doi.org
Reposted by José Molina
ecdc.europa.eu
📈 Imported cases are rising:
1,700 in 2015 → 5,100 in 2023

Now we’re also seeing more local transmission.

👩‍⚕️ ECDC is running weekly enhanced surveillance across the EU/EEA - tracking cases and supporting public health action, including for substances of human origin (#SoHO).

#IDsky #EpiSky
josemolinagb.bsky.social
Agree!
Also, max dose isn’t always about GI tolerance: absorption matters too.

Hydrophilic drugs like BL need transporters in intestinal epithelium that saturate. So beyond a certain dose (e.g.1g amoxicillin), more drug ≠ more exposure!

A review on the topic 👉🏻 www.sciencedirect.com/science/arti...
josemolinagb.bsky.social
You’re right, maybe the term isn’t ideal here.
I think they mean oral cipro can maintain exposure thanks to higher doses than IV.
But oral BLs usually mean lower total doses than their IV equivalents (cefazolin 2g/8h, amox/clav 1g/200mg/8h…).
I had a slide on this from a previous ESCMID Global! 😉
josemolinagb.bsky.social
No, no participamos en la plataforma.
¿El ensayo tiene algún nodo en Europa?
Es una iniciativa estupenda, ¡ánimo con la puesta en marcha! 💪🏼
josemolinagb.bsky.social
Hopefully, we will have data from a RCT to solve the question on the efficacy of oral BL for bacteremic infections and cUTI.

BALANCE has evolved to a platform trial (BALANCE+) which have included this in one of its domains! 🤞🏻🇨🇦 (🧵4/4)

www.ccctg.ca/trials-and-s... #IDsky #UTIsky #AMSsky
josemolinagb.bsky.social
I use early oral high-dose BL if no source issues (abscess or prostathitis), independently on the presence of BSI.

If you have no options other than BL and you have source issues, I would consider delaying oral switch and/or prolong therapy (🧵3’/4)

academic.oup.com/cid/article/... #AMSsky #UTIsky
Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia
In a multicenter study of 1099 hospitalized adults with complicated urinary tract infections and associated bacteremia, 7 days of antibiotics was sufficien
academic.oup.com
josemolinagb.bsky.social
I think that avoiding oral BL for the fear of an unlikely relapse should be balanced with the risks of the alternatives: prolonging hospitalization/iv or using drugs (FQ or TMP/SMX) which may have a worse safety profile.

Could be good to discuss patient’s preferences! (🧵3/4)

#UTIsky #AMSsky #IDsky
josemolinagb.bsky.social
A relevant update from the SNAP trial on adjunctive clindamycin, and some thoughtful insights in the thread below!
@steventong.bsky.social
@gurujosh.bsky.social
@seanong.bsky.social @drtoddlee.bsky.social
#AMSsky #IDsky
sebpoule.bsky.social
SNAP trial update

➡️ The DSMC provided a recommendation to close the ADJUNCTIVE domain (Clindamycin), due to a statistical trigger for futility being met.

#IDsky
Reposted by José Molina
idiots-pod.bsky.social
Interesting update for Rx CAP from the USA:

-USS can be used for Dx rather than CXR if ppl are experienced enough
-ABx: 5d or less for nonsevere, 5+ for severe
-Steroids for Severe CAP.

Shorter Is Better continues to spread!
Reposted by José Molina
Reposted by José Molina
jac-amr.bsky.social
This review of tetracycline-resistant Neisseria gonorrhoeae from 51 countries and 80,645 isolates reported high resistance – meaning using doxyPEP is unlikely to be effective in preventing infections
doi.org/10.1093/jaca...
#JACAMRNews
Reposted by José Molina
id-journal.bsky.social
Doxy PEP use among MSM linked to rising NG-tetracycline resistance (27% to 70% by Q2 2024). High-level resistance rose from 2% to 65%. Doxy users had lower S. aureus but higher resistant strains. 📈💊##idsky
Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus
Doxycycline post-exposure prophylaxis (doxy PEP) is increasingly used among men who have sex with men (MSM). Its impact on antimicrobial resistance and the microbiome is uncertain.MethodsWe used Neisseria gonorrhoeae (NG) surveillance data from King County, Washington, USA, and joinpoint regression to investigate trends in NG-tetracycline resistance (tetR), 2017–2024 and, among sexual health clinic (SHC) patients, evaluated the association of NG-tetR with doxy PEP use. We evaluated nasopharyngeal colonization with Staphylococcus aureus and Group A Streptococcus (GAS) in 703 MSM SHC patients, August 2023-July 2024.ResultsAmong 2312 MSM with NG, tetR was stable 2017 to quarter 1 (Q1) 2023 (mean = 27%) and thereafter rose to 70% in Q2 2024 (P < .0001). (King County released doxy PEP guidelines in Q2 2023.) NG with high-level (HL) tetR increased Q1 2021 to Q2 2024 (2% to 65%) (P < .0001). Taking >3 doses of doxy PEP/month was associated with both tetR and HL tetR (P ≤ .01 for both), though any use of doxy PEP was not associated with tetR or HL tetR. S. aureus colonization was less common among doxy PEP users than non-users (27% vs 36%, P = .02), but colonization with both tetracycline-resistant S. aureus and GAS were more common among doxy PEP users than non-users (18% vs 8%, P < .0001% and 9% vs 4%, P = .008, respectively).ConclusionsTetR in NG rapidly increased from 2021 to 2024, and most NG among King County MSM now have HL tetR. Doxy PEP use is associated with colonization with GAS and tetracycline-resistant S. aureus, suggesting that doxy PEP impacts off-target bacteria.
academic.oup.com
Reposted by José Molina
gpollara.bsky.social
Pivmecillinam role in treating uncomplicated UTI is established (esp for many AmpC/ ESBL bacteria).

I wonder if it also has a place in pyelonephritis care. Perhaps as an oral step down once bacillary burden has fallen?
(1/2)

#IDSky #UTISky #MedSky #AMR
Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis
This reanalysis of data from historical randomized, controlled trials, according to criteria published by the US Food and Drug Administration in 2019, conf
academic.oup.com
Reposted by José Molina
id-journal.bsky.social
67% of 31 patients preferred oral antibiotics for mobility & comfort. 74% wanted more info on prescriptions. 39% believed IVs were more effective. Patient insights can enhance antimicrobial stewardship. 💊🩺##idsky
P51 The patient perspective on IV and oral antibiotics
AbstractObjectivesTo explore the patient perspective on the administration of IV and oral antimicrobials.BackgroundImproving IV to Oral antimicrobial switch (IVOS) rates facilitates patient flow, reduces nursing time spent reconstituting iv antibiotics, increases the use of cost-effective antibiotics, reduces the ward level carbon footprint, and decreases the risk of developing line related infections. This work aims to explore patient experience, perception and views, in a secondary care setting, around the administration routes of antimicrobials.MethodsAfter patient consent, a semi-structured interview comprising both open and closed ended questions, was conducted. This allowed clarification or further explanation of answers, providing mid-level insights. Interviews were carried out with 31 patients who were randomly selected across medical wards over one week. Eligible participants were required to have mental capacity, must have received both IV and oral antibiotics for at least 48 h during their hospital admission, and consented to participate in the interview.ResultsOral antibiotics were preferred by 67% (16/24) of patients, as they enabled them to ‘move around and go to the shops’, they can ‘go home on them’, and many expressed a preference for avoiding needles when possible, stating they would ‘rather swallow a tablet than have a needle’. Those who preferred IV antibiotics felt IVs helped them ‘get better quicker’, and a patient felt ‘oral antibiotics disturbed my stomach’. When asked whether patients felt IV antibiotics were more effective than oral, 32% (12/31) patients were unsure, as ‘they did not know how they work’, 23% (7/31) patients felt that IV were not more effective as ‘they are the same thing’ and ‘oral is better’, and 39% (12/31) patients felt that IV antibiotics were more effective as they ‘go straight into the bloodstream’, and ‘have worked in the past’. When asked if they required more information on their prescribed antibiotics, 8/31 (23%) of patients felt they had been adequately informed. From the sample of 31 patients, 74% of participants expressed how they would like more information around the antibiotics prescribed for them, why and how they are given to them while in hospital.ConclusionsProviding patients with the opportunity to discuss and receive additional information regarding antimicrobials prescribed would be valued. The patients interviewed have built perceptions around antibiotic administration routes based on previous experiences. Patient targeted approaches to antimicrobial stewardship would be well received, potentially challenging existing beliefs and empowering patients.
academic.oup.com